Conclusion:In patients with metastatic non-squamous NSCLC, pembrolizumab plus standard chemotherapy of platinum and pemetrexed as the first-line treatment is not cost-effective in China, regardless of TPS. First-Line Pembrolizumab Plus Chemotherapy for Patients
- BackgroundMethodsResultsConclusionsEditorial AcknowledgementDisclosurePembrolizumab (pembro) + carboplatin and paclitaxel/nab-paclitaxel significantly improved OS and PFS vs placebo in patients (pts) with previously untreated stage IV squamous NSCLC in the phase III KEYNOTE-407 study (NCT02775435). At protocol-specified final analysis (data cutoff May 9, 2019), HR for OS was 0.71 (95% CI, 0.580.88). We report long-term data and outcomes for pts who completed 35 cycles (2 y) of treatment.Pembrolizumab plus cetuximab in patients with recurrent or May 11, 2021 · Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are active as single agents and in combination with cytotoxic chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Jun 04, 2021 · Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med . 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865 PubMed Google Scholar Crossref See Pembrolizumab plus chemotherapy approved for squamous The FDA approved pembrolizumab (Keytruda®) plus carboplatin and (nab-)paclitaxel for first-line metastatic squamous non-small cell lung cancer (NSCLC). Pembrolizumab plus chemotherapy effective in squamous Oct 07, 2018 · Standard first-line therapy for metastatic, squamous NSCLC is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] eion on 50% of tumour cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.
Mar 09, 2020 · Until the advent of immunotherapy, first-line treatment of patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC) without an EGFR / ALK alteration was platinum-based chemotherapy, with addition of bevacizumab as an option in select patients. 1, 2 The introduction of pembrolizumab, an antiprogrammed death-1 (PD-1) monoclonal antibody, has altered the Pembrolizumab plus Chemotherapy in Metastatic NonSmall
- TreatmentScopeAdministrationTrialAssessmentAnalysisResultsStatisticsPrognosisAdverse effectsSociety and cultureFundingParticipantsPembrolizumab plus chemotherapy-induced pneumonitis in Methods:We conducted a 36-centre, retrospective cohort study in patients with chemo-naïve advanced non-squamous non-small cell lung cancer who received a combination of platinum, pemetrexed and pembrolizumab between December 2018 and June 2019. Results:The study comprised 299 patients. The most frequent grade 3 non-hematologic adverse event was pneumonitis.